Literature DB >> 10654805

Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis.

J Koskinas1, I Raptis, Z Manika, S Hadziyannis.   

Abstract

We describe the case of a 18-year-old male patient who first presented with decompensated cirrhosis, fever and generalized lymphadenopathy. He had abnormal results for liver biochemical tests, with a hepatitic-like picture and high titre of antinuclear antibodies. According to the scoring system proposed by the International Autoimmune Hepatitis Group he had 'definite' autoimmune hepatitis and responded well to immunosuppressive treatment. One year later he developed pyoderma gangrenosum which was successfully treated with cyclosporine. Two years later he experienced bloody diarrhoea as a first presentation of ulcerative colitis. At that time both the cholestatic biochemical picture and the cholangiographic appearances of the biliary tree were consistent with primary sclerosing cholangitis. Despite the addition of azathioprine and ursodeoxycholic acid to his treatment regime he developed recurrent episodes of cholangitis and intractable pruritus for which he underwent successful liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654805     DOI: 10.1097/00042737-199912000-00014

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  3 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with ulcerative colitis.

Authors:  Richard G Lucas; Edward Y Lee
Journal:  Pediatr Radiol       Date:  2007-05-10

Review 3.  A case report of successful treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis, and review of the literature.

Authors:  Theodoros Androutsakos; Paraskevas Stamopoulos; Kiriaki Aroni; Gregorios Hatzis
Journal:  BMC Gastroenterol       Date:  2015-10-26       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.